The Booth Gardner Parkinson’s Care Center is conducting a phase 2a open label study to find out if an intravenous, investigational drug is well tolerated and safe in subjects with Huntington’s disease or at risk for Huntington’s disease.
Who may be eligible to participate?
Male or female patients, age 18 and older, who have Huntington’s Disease or are at risk for Huntington’s disease.
Other inclusion/exclusion criteria apply.
What does participation involve?
Enrolled subjects will receive the investigational drug intravenously on Day 1, Day 5 or 6 and then every two weeks on Week 2, 4, 6, 8 and 10.
The maximum duration of patient participation is approximately seven months. Subjects will also be contacted six months after study completion for a phone visit.
Pinky Agarwal, MD, FAAN, EvergreenHealth Parkinson's Care